Rate Of Return
Steady achieverGlobal pharmaceutical giant, $Merck(MRK.US) announced its Q4 financial report, showing
a 7% year-on-year revenue increase to $15.62 billion;
adjusted EPS of $1.72;
As for future outlook, 2025 revenue expectations are lower than market projections, and the company announced it will suspend supply of HPV vaccine GARDASIL to China starting February, expected to last at least until mid-year;
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
